Epirubicin hydrochloride and Halaven drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Epirubicin hydrochloride (epirubicin hydrochloride) and Halaven (eribulin mesylate). Common drug interactions include osteonecrosis of jaw among females.

The phase IV clinical study analyzes what interactions people have when they take Epirubicin hydrochloride and Halaven. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Epirubicin hydrochloride?

Epirubicin hydrochloride has active ingredients of epirubicin hydrochloride. eHealthMe is studying from 5,419 Epirubicin hydrochloride users. Check the latest studies of Epirubicin hydrochloride.

What is Halaven?

Halaven has active ingredients of eribulin mesylate. eHealthMe is studying from 3,881 Halaven users. Check the latest studies of Halaven.

On Jul, 20, 2026

12 people who take Epirubicin hydrochloride and Halaven together, and have interactions are studied.

Epirubicin hydrochloride and Halaven drug interactions.

What are the common drug interactions of Epirubicin Hydrochloride and Halaven, by gender? *:

female:

Osteonecrosis of jaw (death of bone of jaw)
Brain abscess
Malignant neoplasm progression (cancer tumour came back)
Metastases to bone (cancer spreads to bone)
Metastases to lymph nodes (cancer spreads to lymph node)
Nausea (feeling of having an urge to vomit)
Pain in extremity
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pneumonia
Cardiac failure

male:

n/a

What are the common drug interactions of Epirubicin Hydrochloride and Halaven, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Osteonecrosis of jaw (death of bone of jaw)

50-59:

Osteonecrosis of jaw (death of bone of jaw)
Brain abscess
Cardiac failure

60+:

Decreased appetite
Discomfort
Pneumonia
Drug ineffective
Malaise (a feeling of general discomfort or uneasiness)
Malignant neoplasm progression (cancer tumour came back)
Metastases to bone (cancer spreads to bone)
Metastases to lymph nodes (cancer spreads to lymph node)
Nausea (feeling of having an urge to vomit)
Pain in extremity

What are the existing conditions these people have? *

Breast Cancer: 6 people, 50.00%
Metastases To Bone (cancer spreads to bone): 4 people, 33.33%
Neuralgia (pain in one or more nerves): 1 person, 8.33%
Nausea (feeling of having an urge to vomit): 1 person, 8.33%
Metastases To Lung (cancer spreads to lung): 1 person, 8.33%
Iron Deficiency Anaemia: 1 person, 8.33%
Gastritis (inflammation of stomach): 1 person, 8.33%
Constipation: 1 person, 8.33%
Cancer Pain: 1 person, 8.33%
Breast Cancer Recurrent: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Epirubicin hydrochloride and Halaven?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously